SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Caplin Martyn E.)
 

Sökning: WFRF:(Caplin Martyn E.) > Srirajaskanthan Rajaventhan > Symptom Diaries of ...

  • Strosberg, Jonathan R.H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. (författare)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-03-26
  • Society of Nuclear Medicine,2021
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-462222
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-462222URI
  • https://doi.org/10.2967/jnumed.120.258897DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Title in Web of Science: Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with Lu-177-DOTATATE
  • We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome.Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures.Results: Patients (intent-to-treat) who received 177Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For 177Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 d per 4 wk, respectively, compared with 0.99, 1.44, and 2.54 d for high-dose octreotide LAR. The mean differences were 3.11 d (95% CI, 1.35–4.88; P = 0.0007) for abdominal pain, 3.11 d (1.18–5.04; P = 0.0017) for diarrhea, and 1.98 d (0.08–3.88; P = 0.0413) for flushing, favoring 177Lu-DOTATATE. A positive repeated-measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing.Conclusion: In addition to efficacy and quality-of-life benefits, symptom diaries from NETTER-1 demonstrated that treatment with 177Lu-DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut neuroendocrine tumors, compared with high-dose octreotide LAR, supporting a beneficial effect of 177Lu-DOTATATE on health-related quality of life.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Srirajaskanthan, RajaventhanKings Coll Hosp London, Dept Gastroenterol, Neuroendocrine Tumour Unit, London, England. (författare)
  • El-Haddad, GhassanH Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. (författare)
  • Wolin, Edward M.Tish Canc Inst Mt Sinai, Ctr Carcinoid & Neuroendocrine Tumors, New York, NY USA. (författare)
  • Chasen, Beth R.Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Div Diagnost Imaging, Houston, TX 77030 USA. (författare)
  • Kulke, Matthew H.Boston Univ, Sect Hematol & Med Oncol, Boston, MA 02215 USA.;Boston Med Ctr, Boston, MA 02215 USA. (författare)
  • Bushnell, David L.Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA. (författare)
  • Caplin, Martyn E.Royal Free Hosp, Neuroendocrine Tumour Unit, London, England. (författare)
  • Baum, Richard P.DKD Helios Clin, Curanosticum Wiesbaden Frankfurt, Wiesbaden, Germany. (författare)
  • Hendifar, Andrew E.Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. (författare)
  • Öberg, Kjell,1946-Uppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob (författare)
  • Ruszniewski, PhilippeDiv Gastroenterol & Pancreatol, Hop Beaujon, Clichy, France. (författare)
  • Santoro, PaolaAdv Accelerator Applicat, Millburn, NJ USA. (författare)
  • Broberg, PerAdv Accelerator Applicat, Geneva, Switzerland. (författare)
  • Leeuwenkamp, Oscar R.Adv Accelerator Applicat, Geneva, Switzerland. (författare)
  • Krenning, Eric P.Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, Netherlands. (författare)
  • H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.Kings Coll Hosp London, Dept Gastroenterol, Neuroendocrine Tumour Unit, London, England. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Nuclear Medicine: Society of Nuclear Medicine62:12, s. 1712-17180161-55051535-56672159-662X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy